MX2020012979A - Métodos para aumentar la exposición al plasma de sepiapterina. - Google Patents
Métodos para aumentar la exposición al plasma de sepiapterina.Info
- Publication number
- MX2020012979A MX2020012979A MX2020012979A MX2020012979A MX2020012979A MX 2020012979 A MX2020012979 A MX 2020012979A MX 2020012979 A MX2020012979 A MX 2020012979A MX 2020012979 A MX2020012979 A MX 2020012979A MX 2020012979 A MX2020012979 A MX 2020012979A
- Authority
- MX
- Mexico
- Prior art keywords
- sepiapterin
- methods
- plasma exposure
- increasing plasma
- csf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677943P | 2018-05-30 | 2018-05-30 | |
| US201862771398P | 2018-11-26 | 2018-11-26 | |
| US201962822376P | 2019-03-22 | 2019-03-22 | |
| GC201937663 | 2019-05-28 | ||
| PCT/US2019/034523 WO2019232130A1 (en) | 2018-05-30 | 2019-05-30 | Methods for increasing sepiapterin plasma exposure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012979A true MX2020012979A (es) | 2021-04-29 |
Family
ID=68699037
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012979A MX2020012979A (es) | 2018-05-30 | 2019-05-30 | Métodos para aumentar la exposición al plasma de sepiapterina. |
| MX2024005935A MX2024005935A (es) | 2018-05-30 | 2020-11-30 | Metodos para aumentar la exposicion al plasma de sepiapterina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005935A MX2024005935A (es) | 2018-05-30 | 2020-11-30 | Metodos para aumentar la exposicion al plasma de sepiapterina. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11617752B2 (https=) |
| EP (2) | EP3801536B1 (https=) |
| JP (2) | JP7502197B2 (https=) |
| CN (1) | CN112703002A (https=) |
| AU (2) | AU2019277382B2 (https=) |
| CA (1) | CA3102106A1 (https=) |
| DK (1) | DK3801536T3 (https=) |
| ES (1) | ES2986920T3 (https=) |
| FI (1) | FI3801536T3 (https=) |
| HR (1) | HRP20241213T1 (https=) |
| HU (1) | HUE068589T2 (https=) |
| LT (1) | LT3801536T (https=) |
| MD (1) | MD3801536T2 (https=) |
| MX (2) | MX2020012979A (https=) |
| PL (1) | PL3801536T3 (https=) |
| PT (1) | PT3801536T (https=) |
| RS (1) | RS65874B1 (https=) |
| SI (1) | SI3801536T1 (https=) |
| SM (1) | SMT202400430T1 (https=) |
| WO (1) | WO2019232130A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11072614B2 (en) | 2016-11-29 | 2021-07-27 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
| US11130760B2 (en) | 2016-11-29 | 2021-09-28 | Ptc Therapeutics Mp, Inc. | Polymorphic form of sepiapterin |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| EP3801536B1 (en) | 2018-05-30 | 2024-07-17 | PTC Therapeutics MP, Inc. | Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure |
| CN112654356A (zh) | 2018-05-30 | 2021-04-13 | Ptc医疗Mp公司 | 增加四氢生物蝶呤血浆暴露的组合物和方法 |
| CA3165636A1 (en) * | 2020-01-24 | 2021-07-29 | Neil Smith | Methods for treating parkinson's disease with sepiapterin |
| US20230077104A1 (en) * | 2020-02-19 | 2023-03-09 | The United States Government As Represented By The Department Of Veteran Affairs | L-sepiapterin and methods of use for treating diseases and disorders |
| JP2024506336A (ja) * | 2021-02-09 | 2024-02-13 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | 膠芽腫の治療方法 |
| EP4291196A1 (en) * | 2021-02-09 | 2023-12-20 | PTC Therapeutics MP, Inc. | Methods for treating covid-19 with sepiapterin |
| CN120732846A (zh) * | 2025-04-09 | 2025-10-03 | 中南大学湘雅医院 | 吲哚乙酸在制备预防或治疗高血压产品中的用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) * | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| CA2228970A1 (en) | 1995-08-18 | 1997-02-27 | Donald W. Landry | Detection of organic compounds through regulation of antibody-catalyzed reactions |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| EP1696877A4 (en) * | 2003-11-13 | 2010-06-09 | Gen Hospital Corp | PROCESS FOR PAIN TREATMENT |
| US7732599B2 (en) | 2003-11-17 | 2010-06-08 | Biomarin Pharmaceutical Inc. | Process for preparing tetrahydrobiopterin and analogs of tetrahydrobiopterin |
| KR20070005550A (ko) | 2003-11-17 | 2007-01-10 | 바이오마린 파머수티컬 인크. | 대사 장애 치료를 위한 조성물 및 방법 |
| CA2678125C (en) | 2003-11-17 | 2014-10-14 | Merck Eprova Ag | Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride |
| WO2006055511A2 (en) | 2004-11-17 | 2006-05-26 | Biomarin Pharmaceutical Inc. | Stable tablet formulation of tetrahydrobiopterin |
| CA2588994A1 (en) | 2004-12-08 | 2006-06-15 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| US7582799B2 (en) | 2005-04-28 | 2009-09-01 | Shiratori Pharmaceutical Co., Ltd. | Method for producing hydrazone derivatives |
| US20080075666A1 (en) | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| WO2008128049A2 (en) | 2007-04-11 | 2008-10-23 | Biomarin Pharmaceutical Inc. | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
| US20110144117A1 (en) | 2008-08-12 | 2011-06-16 | Orpha Swiss Gmbh | Pharmaceutical Dosage Form Containing Tetrahydrobiopterin |
| EP2562176B1 (en) | 2010-04-22 | 2018-08-15 | Nihon University | Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| CA2828685C (en) | 2011-03-01 | 2018-05-29 | Rubicon Research Private Limited | Stable compositions of tetrahydrobiopterin |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| IN2014DN09053A (https=) | 2012-05-07 | 2015-05-22 | Shiratori Pharm | |
| US10365267B2 (en) | 2014-10-31 | 2019-07-30 | Children's Medical Center Corporation | Methods and assays relating to sepiapterin reductase inhibition |
| US11130760B2 (en) | 2016-11-29 | 2021-09-28 | Ptc Therapeutics Mp, Inc. | Polymorphic form of sepiapterin |
| US11072614B2 (en) | 2016-11-29 | 2021-07-27 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| KR102895167B1 (ko) * | 2017-11-23 | 2025-12-04 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 표시 장치 및 전자 기기 |
| AU2019277372B2 (en) | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| CN112654356A (zh) * | 2018-05-30 | 2021-04-13 | Ptc医疗Mp公司 | 增加四氢生物蝶呤血浆暴露的组合物和方法 |
| EP3801536B1 (en) | 2018-05-30 | 2024-07-17 | PTC Therapeutics MP, Inc. | Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure |
| IL290321B1 (en) | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
-
2019
- 2019-05-30 EP EP19811888.7A patent/EP3801536B1/en active Active
- 2019-05-30 SI SI201930841T patent/SI3801536T1/sl unknown
- 2019-05-30 JP JP2020566655A patent/JP7502197B2/ja active Active
- 2019-05-30 MD MDE20210340T patent/MD3801536T2/ro unknown
- 2019-05-30 RS RS20240943A patent/RS65874B1/sr unknown
- 2019-05-30 CA CA3102106A patent/CA3102106A1/en active Pending
- 2019-05-30 PL PL19811888.7T patent/PL3801536T3/pl unknown
- 2019-05-30 SM SM20240430T patent/SMT202400430T1/it unknown
- 2019-05-30 FI FIEP19811888.7T patent/FI3801536T3/fi active
- 2019-05-30 ES ES19811888T patent/ES2986920T3/es active Active
- 2019-05-30 AU AU2019277382A patent/AU2019277382B2/en active Active
- 2019-05-30 DK DK19811888.7T patent/DK3801536T3/da active
- 2019-05-30 LT LTEPPCT/US2019/034523T patent/LT3801536T/lt unknown
- 2019-05-30 HR HRP20241213TT patent/HRP20241213T1/hr unknown
- 2019-05-30 US US17/059,719 patent/US11617752B2/en active Active
- 2019-05-30 CN CN201980050839.7A patent/CN112703002A/zh active Pending
- 2019-05-30 WO PCT/US2019/034523 patent/WO2019232130A1/en not_active Ceased
- 2019-05-30 MX MX2020012979A patent/MX2020012979A/es unknown
- 2019-05-30 EP EP24187175.5A patent/EP4454704A3/en active Pending
- 2019-05-30 HU HUE19811888A patent/HUE068589T2/hu unknown
- 2019-05-30 PT PT198118887T patent/PT3801536T/pt unknown
-
2020
- 2020-11-30 MX MX2024005935A patent/MX2024005935A/es unknown
-
2023
- 2023-03-31 US US18/129,177 patent/US12329757B2/en active Active
-
2024
- 2024-02-05 JP JP2024015822A patent/JP7841005B2/ja active Active
-
2025
- 2025-02-06 AU AU2025200814A patent/AU2025200814A1/en active Pending
- 2025-05-13 US US19/206,193 patent/US20260091037A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112703002A (zh) | 2021-04-23 |
| EP3801536A1 (en) | 2021-04-14 |
| EP4454704A3 (en) | 2025-01-01 |
| US12329757B2 (en) | 2025-06-17 |
| EP3801536B1 (en) | 2024-07-17 |
| JP2024069192A (ja) | 2024-05-21 |
| ES2986920T3 (es) | 2024-11-13 |
| LT3801536T (lt) | 2024-09-25 |
| HUE068589T2 (hu) | 2025-01-28 |
| SMT202400430T1 (it) | 2024-11-15 |
| US11617752B2 (en) | 2023-04-04 |
| EP3801536A4 (en) | 2022-03-23 |
| US20230381181A1 (en) | 2023-11-30 |
| EP4454704A2 (en) | 2024-10-30 |
| SI3801536T1 (sl) | 2024-12-31 |
| MD3801536T2 (ro) | 2024-11-30 |
| PL3801536T3 (pl) | 2025-02-03 |
| HRP20241213T1 (hr) | 2024-11-22 |
| PT3801536T (pt) | 2024-09-19 |
| RS65874B1 (sr) | 2024-09-30 |
| US20210220363A1 (en) | 2021-07-22 |
| FI3801536T3 (fi) | 2024-08-29 |
| AU2025200814A1 (en) | 2025-02-27 |
| DK3801536T3 (da) | 2024-08-19 |
| JP7502197B2 (ja) | 2024-06-18 |
| WO2019232130A1 (en) | 2019-12-05 |
| MX2024005935A (es) | 2024-06-04 |
| AU2019277382B2 (en) | 2025-01-09 |
| JP2021525729A (ja) | 2021-09-27 |
| AU2019277382A1 (en) | 2021-01-21 |
| CA3102106A1 (en) | 2019-12-05 |
| JP7841005B2 (ja) | 2026-04-06 |
| US20260091037A1 (en) | 2026-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020012979A (es) | Métodos para aumentar la exposición al plasma de sepiapterina. | |
| AR132544A2 (es) | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| CL2019001978A1 (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo. | |
| MX2019012445A (es) | Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. | |
| CR20160485A (es) | Compuesto de ciclopropanamina y sus usos | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2020001855A (es) | Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides. | |
| UY35962A (es) | Formulaciones de liberación modificada de pridopidina | |
| CL2022001178A1 (es) | Ligandos de la pseudoquinasa tyk2 | |
| CL2021000163A1 (es) | Anticuerpos anti-htra1 y metodos de usos de los mismos. (divisional de solicitud 201801139) | |
| MX386547B (es) | Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer. | |
| MX2020003593A (es) | Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos. | |
| MX2019000980A (es) | Compuestos y composiciones y usos de los mismos. | |
| BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
| AR115583A1 (es) | Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado | |
| BR112017011226A2 (pt) | peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica | |
| AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
| MX380290B (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. | |
| MX2022013283A (es) | Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales. | |
| IT201600081379A1 (it) | Composizione farmaceutica per uso nel trattamento delle patologie prostatiche. | |
| CL2021000930A1 (es) | Piridazinas novedosas | |
| MX374705B (es) | Composiciones que comprenden anakinra. | |
| CL2020000251A1 (es) | Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico. | |
| BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| UY36331A (es) | Composición farmacéutica sólida que comprende amlodipina y losartán |